Psoriasis – Landscape & Forecast – Disease Landscape & Forecast
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) is increasingly being challenged by novel, highly effective IL-17 and IL-23 inhibitors. In particular, the uptake of risankizumab (AbbVie’s Skyrizi)—the latest IL-23 inhibitor to be approved for psoriasis—has been phenomenal, raising an alarm for other approved biologics. The anticipated approvals of bimekizumab (in the United States), an IL-17 inhibitor; deucravacitinib, an oral tyrosine kinase (TYK)2 inhibitor; and the nonsteroidal topical agents roflumilast and tapinarof will further increase the number of psoriasis treatments and make the market even more competitive.
Questions answered:
- How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq/Lumicef) and the emerging IL-17 A/F dual inhibitor bimekizumab, and where are/will these agents be positioned in the psoriasis treatment algorithm?
- What will be the impact of newer IL-23 inhibitors (Ilumya and Skyrizi) on TNF-alpha inhibitors, anti-IL-17s, and the first-in-class IL-23 inhibitor, Tremfya? How are/will these newer agents fare in the competitive psoriasis market?
- How will the oral TYK2 inhibitor deucravacitinib affect apremilast’s (Amgen’s Otezla) patient share, and how will the two agents compare on efficacy and safety attributes?
- What will be the future of the novel topical therapies roflumilast, a PDE-4 inhibitor, and tapinarof, a TAMA?
Content highlights:
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 31 country-specific interviews with thought leaders. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.
Emerging therapies: Phase III/PR: 6 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.
Forecast: 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2030, segmented by brands/generics and epidemiological subpopulations.
Product description:
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement:
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Psoriasis - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- Q2 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2021
- December 2021
- November 2021
- Q3 2021
- August 2021
- July 2021
- Q2 2021
- June 2021
- May 2021
- April 2021
- Q1 2021
- March 2021
- February 2021
- Q2 2022
- Key Findings
- Market Outlook
- Key Findings
- Market Share of Psoriasis Drug Classes in 2020
- Market Share of Psoriasis Drug Classes in 2030
- Psoriasis SWOT Analysis
- Market Drivers and Constraints
- What Factors Are Constraining the Market for Psoriasis?
- Major-Market Sales of Select Drug Classes in Psoriasis: 2020-2030
- Annual Sales of Biologics and Key Oral Agents in Psoriasis: 2020-2030
- Drug-Class-Specific Trends
- Patient Share of TNF-Alpha Inhibitors in Moderate to Severe Psoriasis by Country: 2020-2030
- Brand and Biosimilar Patient Share for TNF-Alpha Inhibitors in Psoriasis: 2020-2030
- Major-Market Sales of TNF-Alpha Inhibitors and IL-12/23 Inhibitors in Moderate to Severe Psoriasis: 2020-2030
- Major-Market Patient Share of TNF-Alpha Inhibitors, IL-12/23 Inhibitors, and IL-17 Inhibitors in Moderate to Severe Psoriasis: 2020-2030
- Major-Market Patient Share of TNF-Alpha Inhibitors, IL-12/23 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors in Moderate to Severe Psoriasis: 2020-2030
- TYK2 Inhibitors
- Major-Market Sales of Biologics and Novel Oral Therapies in Moderate to Severe Psoriasis: 2020-2030
- Major-Market Patient Share of Traditional Oral Drug Classes, PDE-4 Inhibitors, A3 Adenosine Receptor Agonists, and TYK2 Inhibitors in Moderate to Severe Psoriasis: 2020-2030
- Major-Market Sales of Traditional Oral Drug Classes, PDE4 Inhibitors, A3 Adenosine Receptor Agonists, and TYK2 Inhibitors in Moderate to Severe Psoriasis: 2020-2030
- Key Findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Etiology
- Risk Factors
- Pathophysiology
- Clinical Features
- Typical Locations of Psoriasis Lesions
- Classification of Psoriasis Vulgaris by Phenotype
- Clinical Forms of Psoriasis
- Key Pathways and Drug Targets
- Pathogenesis of Psoriasis and Therapeutic Targets
- Pathogenesis and Drug Targets
- Etiology
- Epidemiology
- Key Findings
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Diagnosed Symptomatic Prevalence of Psoriasis
- Number of Diagnosed Symptomatic Prevalent Cases of Psoriasis in the Major Pharmaceutical Markets:u00a02020-2030 (thousands)
- Disease Definition
- Methods
- Sources Used for Diagnosed Symptomatic Prevalent Psoriasis by Severity
- Sources Used for Drug-Treated Cases of Psoriasis
- Number of Diagnosed and Drug-Treated Prevalent Cases of Mild Psoriasis in the Major Pharmaceutical Markets: 2020-2030 (thousands)
- Number of Diagnosed and Drug-Treated Prevalent Cases of Moderate to Severe Psoriasis in the Major Pharmaceutical Markets: 2020-2030 (thousands)
- Key Findings
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Psoriasis
- Key Physician Insights on Clinical Endpoints
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Psoriasis
- Current Therapies Used for Mild Psoriasis
- Current Therapies Used for Moderate to Severe Psoriasis
- Market Events Impacting the Use of Key Current Therapies in Psoriasis
- Advantages and Disadvantages of Etanercept
- Expert Insight: Etanercept
- Advantages and Disadvantages of Infliximab
- Expert Insight: Infliximab
- Advantages and Disadvantages of Adalimumab
- Expert Insight: Adalimumab
- Certolizumab Pegol
- Advantages and Disadvantages of Certolizumab Pegol
- Expert Insight: Certolizumab Pegol
- Advantages and Disadvantages of Ustekinumab
- Expert Insight: Ustekinumab
- Advantages and Disadvantages of Secukinumab
- Expert Insight: Secukinumab
- Ongoing Clinical Development of Cosentyx
- Key Ongoing Clinical Trials of Cosentyx in the Treatment of New-Onset Moderate to Severe Psoriasis
- Advantages and Disadvantages of Ixekizumab
- Expert Insight: Ixekizumab
- Advantages and Disadvantages of Brodalumab
- Expert Insight: Brodalumab
- Advantages and Disadvantages of Guselkumab
- Expert Insight: Guselkumab
- Advantages and Disadvantages of Tildrakizumab
- Expert Insight: Tildrakizumab
- Advantages and Disadvantages of Risankizumab
- Expert Insight: Risankizumab
- Advantages and Disadvantages of Apremilast
- Expert Insight: Apremilast
- Advantages and Disadvantages of Conventional Systemic Therapies
- Expert Insight: Conventional Systemic Therapies
- Advantages and Disadvantages of Topical Therapies
- Expert Insight: Topical Therapies
- Medical Practice
- Overview
- Drug Selection
- Factors Influencing Drug Selection in Moderate to Severe Psoriasis
- Preferred Treatment of Psoriasis by Disease Location and Comorbidities
- Region-Specific Treatment Practices
- Treatment Decision Tree for Psoriasis: United States
- Treatment Decision Tree for Psoriasis: France
- Treatment Decision Tree for Psoriasis: Germany
- Treatment Decision Tree for Psoriasis: Italy
- Treatment Decision Tree for Psoriasis: Spain
- Treatment Decision Tree for Psoriasis: United Kingdom
- Treatment Decision Tree for Psoriasis: Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Psoriasis
- Top Unmet Needs in Psoriasis: Current and Future Attainment
- Expert Insight: Unmet Needs in Moderate to Severe Psoriasis
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Emerging Therapies
- Key Findings
- Key Emerging Therapies
- Therapies in Late-Phase Development for Psoriasis
- Estimated Launch Dates of Key Emerging Therapies for the Treatment of Psoriasis
- Bimekizumab Profile
- Key Ongoing Clinical Trials of Bimekizumab in the Treatment of Psoriasis
- Analysis of the Clinical Development Program for Bimekizumab
- Expert Insight: Bimekizumab
- Expectations for Launch and Sales Opportunity of Bimekizumab in Psoriasis
- Piclidenoson Profile
- Analysis of the Clinical Development Program for Piclidenoson
- Expert Insight: Piclidenoson
- Expectations for Launch and Sales Opportunity of Piclidenoson in Psoriasis
- Likely Uses of Piclidenoson in the Treatment of Psoriasis
- BMS-986165 Profile
- Key Ongoing Clinical Trials of BMS-986165 in the Treatment of Psoriasis
- Analysis of the Clinical Development Program for BMS-986165
- Expert Insight: BMS-986165
- Expectations for Launch and Sales Opportunity of BMS-986165 in Psoriasis
- Likely Uses of BMS-986165 in the Treatment of Psoriasis
- Pefcalcitol Profile
- Analysis of the Clinical Development Program for Pefcalcitol
- Expectations for Launch and Sales Opportunity of Pefcalcitol in Psoriasis
- Tapinarof Profile
- Analysis of the Clinical Development Program for Tapinarof
- Expert Insights: Tapinarof
- Expectations for Launch and Sales Opportunity of Tapinarof in Psoriasis
- Roflumilast Profile
- Key Ongoing Clinical Trials of Roflumilast in the Treatment of Psoriasis
- Analysis of the Clinical Development Program for Roflumilast
- Expert Insight: Roflumilast
- Expectations for Launch and Sales Opportunity of Roflumilast in Psoriasis
- Early-Phase Pipeline Analysis
- Select Compounds in Early-Phase Development for Psoriasis
- Key Discontinuations and Failures in Psoriasis
- Key Findings
- Access & Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Psoriasis: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Psoriasis: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Psoriasis: Japan
- General Reimbursement Environment: Japan
- Region-Specific Reimbursement Practices
- Appendix
- Psoriasis Bibliography
- Key Updates
Mohit Nasa, M.B.A., is a principal analyst on the Immune and Inflammatory Disorders team at Clarivate. He has authored content on such indications as systemic lupus erythropoiesis, psoriasis, asthma, and rheumatoid arthritis. Previously, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for Novartis’s asthma brand Xolair. Mr. Nasa holds a bachelor’s degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.